NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the results of studies on Lyrica® (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu. The studies included exploratory research designed to provide new insight into how Lyrica works in the brains of patients with fibromyalgia. A total of seven Lyrica abstracts were presented.
